There has been some pushback on FDA because the report was heavily redacted (see below), leaving out information on the the company that was involved.
https://www.fda.gov/media/191770/download
Salmonella Saintpaul/Mango/Nov 2025 - CARA ID 1353
On November 20, 2025, FDA’s Office of Coordinated Outbreak Response, Evaluation, and Emergency Preparedness (CORE) was notified by the Centers for Disease Control and Prevention (CDC) of a Salmonella enterica serovar Saintpaul cluster investigation (PulseNet ID: ). On November 21, 2025, state and local health departments began interviewing ill people with the CDC National Hypothesis Generating Questionnaire (NHGQs). By the end of December, CDC identified mango as a vehicle of interest. On December 19, 2025, FDA CORE initiated traceback on mango exposures of six cases from points of service (POS), including traceback legs, with separate supply chains: . The traceback investigation identified common mango importer, . firms could explain all case exposures for the timeframe of interest:
Identification of the exact source was not possible due to the absence of brand information or detailed product information on shopper records, cases refusing or unable to share shopper records, incomplete grower records from the importer of record, comingling of product lots in shipments, and lack of lot code traceability both within production facilities and from distribution centers to retail locations. For-cause inspections were not conducted during this investigation. Increased screening was implemented for suppliers of mango to . Samples were not collected due to the timing of identification of the firms and (b)(4) the end of the harvest season in . Due to a strong epidemiologic association and traceback convergence, this outbreak was confirmed to be associated with mango from . This outbreak resulted in 56 cases reported in states: (b)(5) (b)(5
No comments:
Post a Comment